Wire Stories

PPG divests Traffic Solutions operations in Australia and New Zealand

PITTSBURGH--(BUSINESS WIRE)--PPG (NYSE:PPG) today announced that it has divested all Traffic Solutions operations in Australia and New Zealand to Geveko…

2 years ago

Asia Pacific IT, Business Services Spending Down in Q3, ISG Index™ Shows

Managed services ACV fell 13%, while XaaS spending was down 9% in third quarter SYDNEY--(BUSINESS WIRE)--$III #AsaService--After a strong second…

2 years ago

Triton Digital Releases the Australian Podcast Ranker for September 2023

SYDNEY--(BUSINESS WIRE)--Triton Digital®, the global technology and services leader to the digital audio, podcast, and broadcast radio industries, announced today…

2 years ago

SSR Mining Announces the Sale of Its Sunrise Lake Exploration Property

DENVER--(BUSINESS WIRE)--SSR Mining Inc. (NASDAQ/TSX: SSRM, ASX: SSR) (“SSR Mining” or the “Company”) announced today that it has entered into…

2 years ago

Oneview Healthcare and Baxter Announce Connected Care Collaboration During Meeting with Enterprise Ireland

CHICAGO--(BUSINESS WIRE)--Oneview Healthcare (Oneview), a leading provider of patient experience solutions, and Baxter International Inc. (Baxter), a global medtech leader,…

2 years ago

ClickUp Doubles Down on Investment in APAC with Localised Data Hosting and Regional Hires

ClickUp expands presence in-region to grow impact and better support customers SYDNEY--(BUSINESS WIRE)--ClickUp, the productivity platform that brings work together…

2 years ago

Outstaffer Raises $1.5 Million From Leading Australian Venture Capital Investors

This strategic round of funding enabled the self-funded startup to accelerate growth and launch its SaaS Global Workforce Platform. MELBOURNE,…

2 years ago

BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

First-line tislelizumab plus chemotherapy demonstrated a median overall survival of 15.0 months versus 12.9 months for placebo plus chemotherapy in…

2 years ago

BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)

Late-breaking ESMO data show 56.2% of patients with resectable NSCLC who received tislelizumab plus chemotherapy before surgery achieved major pathological…

2 years ago

FaceMe® Ranks First in NIST FATE Test for Presentation Attack Detection (PAD)

TAIPEI, Taiwan--(BUSINESS WIRE)--CyberLink Corp. (5203.TW), a pioneer in AI and facial recognition technologies, has achieved the highest ranking in the…

2 years ago